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AbstrACt
Introduction The GLOBAL LEADERS is an open-label, 
pragmatic and superiority randomised controlled trial 
designed to challenge the current treatment paradigm of dual 
antiplatelet therapy (DAPT) for 12 months followed by aspirin 
monotherapy among patients undergoing percutaneous 
coronary intervention. By design, all study endpoints are 
investigator reported (IR) and not subject to formal adjudication 
by an independent Clinical Event Committee (CEC), which may 
introduce detection, reporting or ascertainment bias.
Methods and analysis We designed the GLOBAL LEADERS 
Adjudication Sub-StudY (GLASSY) to prospectively implement, 
in a large sample of patients enrolled within the GLOBAL 
LEADERS trial (7585 of 15 991, 47.5%), an independent 
adjudication process of reported and unreported potential 
endpoints, using standardised CEC procedures, in order 
to assess whether 23-month ticagrelor monotherapy 
(90 mg twice daily) after 1-month DAPT is non-inferior to a 
standard regimen of DAPT for 12 months followed by aspirin 
monotherapy for the primary efficacy endpoint of death, non-
fatal myocardial infarction, non-fatal stroke or urgent target 
vessel revascularisation and superior for the primary safety 
endpoint of type 3 or 5 bleeding according to the Bleeding 
Academic Research Consortium criteria. This study will 
comprehensively assess the comparative safety and efficacy 
of the two tested antithrombotic strategies on CEC-adjudicated 
ischaemic and bleeding endpoints and will provide insights 
into the role of a standardised CEC adjudication process on 
the interpretation of study findings by quantifying the level 
of concordance between IR-reported and CEC-adjudicated 
events.
Ethics and dissemination GLASSY has been approved 
by local ethics committee of all study sites and/or by the 
central ethics committee for the country depending on 
country-specific regulations. In all cases, they deemed that 
it was not necessary to obtain further informed consent 
from individual subjects. 
trial registration number NCT01813435.
strengths and limitations of this study
 ► GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) 
is a comprehensive, rigorous and standardised as-
sessment of several non-fatal endpoints as well 
as death (including type, mechanism and relation-
ship to bleeding) in a representative sample of the 
GLOBAL LEADERS trial performed according to best 
practices of adjudication.
 ► An intrinsic limitation is that GLOBAL LEADERS has 
been designed as an investigator-reported (IR)-only 
study. Therefore, systematic identification of study 
endpoints is limited by the electronic case report 
form  (eCRF) and relies on source documentation 
provided by the site, which reduces the ability to 
identify all possible potential endpoints.
 ► For feasibility, GLASSY will be conducted in a sam-
ple rather than the entire parent study, which may 
bias the study towards the null hypothesis of no dif-
ference between IR-adjudicated and Clinical Event 
Committee-adjudicated endpoint by selecting best 
enrolling sites. While this bias is possible, the rela-
tively large study sample (≈50% of the parent study) 
makes this possibility unlikely.
 o
n
 17 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026053 on 9 March 2019. Downloaded from 
2 Leonardi S, et al. BMJ Open 2019;9:e026053. doi:10.1136/bmjopen-2018-026053
Open access 
rAtIonAlE 
The prolonged combination of aspirin and a P2Y12 
receptor inhibitor, typically for 12 months, represents 
the established antiplatelet therapy in patients with or 
without acute coronary syndrome (ACS) undergoing 
percutaneous coronary intervention (PCI) with drug-
eluting stent implantation.1 Clopidogrel, an inconsistent 
P2Y12 receptor inhibitor
2 with considerable variability in 
interpatient response,3 proved inferior to stronger and 
more consistent P2Y12 inhibitors, such as ticagrelor, in 
preventing ischaemic and thrombotic cardiovascular 
events among patients with ACS.4 With the introduction 
and widespread adoption in clinical practice of more 
potent P2Y12 inhibitors, it has been hypothesised that the 
addition of aspirin may yield little additional inhibition 
of platelet aggregation and marginal incremental clin-
ical benefit compared with a strategy based on potent 
P2Y12 receptor inhibitor monotherapy.
5 6 This led to the 
hypothesis that ticagrelor monotherapy may have similar 
efficacy compared with the combination of aspirin and 
ticagrelor and be better tolerated.
The GLOBAL LEADERS trial was designed to challenge 
the current treatment paradigm consisting of 12-month 
dual antiplatelet therapy (DAPT; clopidogrel+aspirin 
among patients with stable coronary artery disease (CAD); 
ticagrelor+aspirin among patients with ACS) followed by 
aspirin monotherapy in patients undergoing PCI based 
on the superiority for the composite endpoint of all-cause 
death or Q-wave myocardial infarction (MI) assessed at 2 
years.7 It is an open-label, randomised comparison testing 
an innovative antithrombotic regimen of 23-month tica-
grelor 90 mg twice daily monotherapy after 1-month 
DAPT (ticagrelor 90 mg twice daily plus low-dose aspirin) 
against conventional 12-month DAPT in all-comer 
patients undergoing PCI with bivalirudin-supported, 
biolimus-eluting stent implantation. The GLOBAL 
LEADERS is a pragmatic clinical trial, and by design, all 
study endpoints are investigator reported (IR) and there-
fore not adjudicated by an independent Clinical Event 
Committee (CEC). Only new Q-wave MI will be identi-
fied by independent core lab assessment and validated 
by a physician blinded to treatment allocation. All other 
endpoints, including specific causes of mortality, non-Q-
wave MI, stroke, stent thrombosis and bleeding will be 
analysed as reported by the local investigators.
Although the use of IR endpoints in a phase III 
randomised trial is a simple and less expensive alterna-
tive, their sole use has potential to introduce detection, 
reporting or ascertainment bias, especially in the absence 
of blinding to randomised treatment (ie, in an open-label 
design as in the case of the GLOBAL LEADERS trial). 
This might challenge the interpretation of the GLOBAL 
LEADERS study results, especially as it relates to the effect 
of the randomly allocated treatment on non-fatal clinical 
endpoints. Moreover, the design of GLOBAL LEADERS 
also raises important questions regarding bleeding 
adverse events that may differ between groups.
We, therefore, designed the GLOBAL LEADERS Adju-
dication Sub-StudY (GLASSY) with the aim to prospec-
tively implement, in a representative sample of patients 
enrolled within the GLOBAL LEADERS trial, an inde-
pendent adjudication process of reported as well as unre-
ported potential endpoints, leveraging on standardised 
CEC procedures. This GLASSY substudy is powered to 
test whether 23-month ticagrelor monotherapy after 
a short course of DAPT for 1 month is non-inferior to 
conventional 12-month DAPT followed by aspirin mono-
therapy with respect to CEC-adjudicated death, non-fatal 
MI, non-fatal stroke or urgent target vessel revascularisa-
tion (TVR) and superior in preventing CEC-adjudicated 
major bleeding. Furthermore, GLASSY will evaluate the 
implications of the CEC adjudication process for the 
interpretation of study results by quantifying the level 
of concordance between IR-reported and CEC-adjudi-
cated events and will define the role of CEC adjudication 
process for the assessment of the efficacy and safety of the 
randomised antithrombotic strategies on a broader set of 
fatal and non-fatal clinical endpoints.
DEsIgn
Parent study
The GLOBAL LEADERS study is a superiority, open-
label, multicentre, randomised controlled trial (RCT) in 
an all-comer population of patients, presenting with ACS 
or stable coronary artery disease, undergoing PCI with 
the uniform use of Biolimus A9-eluting stents (BioMatrix 
BES; Biosensors Europe SA, Morges, Switzerland) and 
receiving bivalirudin at the time of the index procedure 
(figure 1). A total of 15 991 patients have been randomly 
assigned 1:1 to ticagrelor 90 mg twice daily for 24 months 
plus aspirin ≤100 mg daily for 1 month (experimental 
arm) or standard DAPT with either ticagrelor, in case 
of ACS, or clopidogrel, in case of stable coronary artery 
disease, for 12 months plus aspirin ≤100 mg daily for 24 
months (control arm). All study endpoints are IR with 
randomisation stratified by enrolling site as well as clin-
ical presentation. The primary endpoint of the GLOBAL 
LEADERS is the composite of all-cause death or new 
Q-wave MI at 24 months. The presence and date of new 
Q-wave MI will be identified by an independent ECG core 
laboratory and validated by a single physician blinded 
to treatment allocation using adverse events reported in 
the electronic case report form (eCRF) supplemented, if 
required, by additional source documents. The key safety 
endpoint is IR class 3 or 5 bleeding according to the 
Bleeding Academic Research Consortium (BARC) defi-
nitions. Other secondary endpoints include stroke, MI, 
coronary revascularisation and definite stent thrombosis. 
As pragmatic trial, GLOBAL LEADERS implemented a 
risk-based monitoring process for site-based operational 
activities favouring centralised remote monitoring rather 
than in-person on-site monitoring. GLOBAL LEADERS 
terminated enrolment on 9 November 2015.
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objectives
The primary objective of the GLASSY is to assess, in a 
representative subgroup of patients enrolled within the 
GLOBAL LEADERS study, whether 23-month ticagrelor 
monotherapy after a short course of DAPT (1 month) is 
non-inferior to conventional 12-month DAPT followed 
by aspirin monotherapy for the composite endpoint of 
CEC-adjudicated all-cause death, non-fatal MI, non-fatal 
stroke or urgent TVR, and superior in preventing 
CEC-adjudicated major bleeding (BARC types 3 and 5) in 
an all-comers population undergoing PCI at 24 months 
(figure 2). A secondary objective is to quantify the level 
of concordance between IR-adjudicated and CEC-adjudi-
cated endpoints.
Endpoints
GLASSY will have two independent, CEC-adjudicated, 
coprimary endpoints at 24 months:
1. The composite of death, non-fatal MI, non-fatal stroke 
or urgent TVR (coprimary efficacy endpoint).
2. The composite of BARC type 3 or 5 bleeding (coprima-
ry safety endpoint).
Secondary endpoints will include:
 ► Each component of the coprimary composite 
endpoints.
 ► Definite, probable or possible stent thrombosis 
according to Academic Resaerch Consortium  (ARC) 
classification.
 ► Bleeding events according to BARC (primary safety 
endpoint) as well as the alternative Thrombolysis In 
Myocardial Infarction (TIMI) and Global Utilization 
of Streptokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries (GUSTO) classifications.
 ► Type of death (cardiovascular vs non-cardiovascular 
and subtypes).
Figure 1 GLOBAL LEADERS design. ACS, acute coronary 
syndrome; ASA, aspirin;   CAD, coronary artery disease; 
MI, myocardial infarction;  PCI, percutaneous coronary 
intervention.
Figure 2 GLASSY design. CEC, Clinical Event Committee; GLASSY, GLOBAL LEADERS Adjudication Sub-StudY.
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CEC procedures
According to best adjudication practice,8 GLASSY is being 
conducted according to the following features:
Prospective approach to adjudication
The CEC dataset will be locked before the termination 
of the parent study. Suspected events (triggers) will be 
assessed during the conduct of the study rather than 
adjudicating all cases after the study is completed and 
the primary results are available (ie, retrospective adjudi-
cation). In case of updated entry of suspected events or 
updated source documentation by the site after request 
by the CEC team of source documentation, events will be 
re-evaluated for adjudication.
Blinding of randomised treatment allocation
According to the prospective randomized open blinded 
end-point (PROBE) methodology,9 10 the CEC will be 
blinded to randomised treatment allocation.
Several steps will be undertaken to ensure that the CEC 
personnel and physicians remain blinded.
First, any reference to treatment assignment contained 
in the eCRF or source documents that could lead to 
unblinding of treatment assignment will be obliterated by 
using a black marker by the site prior to submission to the 
CEC physician members.
Second, the CEC coordinator and operation personnel 
will obliterate any reference to study drug assignment 
prior to distribution to the physicians if information is 
noted during the preparation of the event packet.
Third, if a reviewer notes the treatment assignment 
during the review of a particular event, the CEC coordi-
nator is notified, and the event is sent for review by the 
third expert reviewer.
Triggering and adjudication of IR as well as non-IR events
All IR events (death, MI, stroke, bleeding, coronary revas-
cularisation and stent thrombosis) will be adjudicated by 
the CEC through dedicated case report forms (CRFs) 
(online online supplementary appendix). We will also 
use comprehensive search strategies for potential cardio-
vascular events that are not reported by the investigator 
via eCRF dedicated queries. Indeed, it may happen that 
patients without IR events or triggers may have expe-
rienced an event qualifying for the endpoints of the 
GLASSY study.10
It is possible that the request of source documen-
tation may trigger endpoint reporting (and bias the 
study towards the null hypothesis). To quantify this, IR 
endpoints entered after CEC requested source documen-
tation will be monitored and reported.
Independent voting processes
Independent voting processes by CEC members with 
at least 3 CEC members (see online supplementary 
appendix A) with knowledge of the geographic varia-
tions of care represented in the trial. Each event will be 
reviewed independently by at least two CEC physicians. 
In case of disagreement, the event will be reviewed by a 
Committee of at least three reviewers with independent 
vote.
Independence from parent study
To maximise the scientific integrity of GLASSY, CEC 
personnel will operate independently from the data 
management group of the parent study, including no 
crosstalk on trigger logic specifications, query processes 
for source documentation and most importantly event 
reporting and adjudication results.
Quantification of sufficient evidence for adjudication of non-fatal 
triggers (no vs unknown events)
Finally, we will quantify the minimum amount of evidence 
required for the assessment of non-fatal endpoints. In 
a randomised trial, a prerequisite to assess whether a 
suspected non-fatal endpoint has occurred or not is the 
availability of sufficient evidence for such an assessment, 
including relevant source documents, tests and/or labo-
ratory exams. While this is commonly performed for fatal 
events (death is adjudicated as ‘unknown’ in case of no or 
insufficient description of death circumstances), it is not 
generally mandatory for non-fatal events.
In GLASSY, we will report all non-fatal endpoints, 
but for each non-fatal trigger examined, an assessment 
will be performed as to whether enough information 
is available for formal adjudication. This will allow 
distinguishing triggers that did not meet the endpoint 
definition (ie, no event with sufficient documentation 
present) from triggers for which this is unknown due to 
insufficient documentation. For each type of non-fatal 
endpoint, the proportion of events with insufficient 
evidence will indirectly estimate: (A) the feasibility of 
GLASSY; (B) the quality of endpoint reported by sites; 
and (C) the uncertainty of the evidence related to the 
studied outcome.
Sufficient evidence for CEC adjudication includes at a 
minimum a narrative description with at least one perti-
nent medical documentation, including ECG/biomarkers 
for MI; angiographic report for stent thrombosis and 
urgent revascularisation; brain imaging for stroke; and 
labs and other appropriate testing for bleeding. In case of 
CRF-only narrative, the evidence will be considered insuf-
ficient, and the case will not undergo CEC adjudication.
Quality control of the adjudication process
To ensure the highest reproducibility, a random sample 
of ≈5% of adjudicated events will be rereviewed by the 
complete CEC committee (ie, three members) who are 
blinded to the initial results.
A major disagreement will be considered if there was a 
disagreement on whether an event had occurred, while a 
minor disagreement is any discordance on the remaining 
adjudicated fields. Major disagreement will be reported 
as part of the final study report and will be used to iden-
tify the presence of systematic problems in the adjudica-
tion process.
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CEC operations
Within the selected study patients, all IR events as well 
as additional potential events (triggers) identified 
through a systematic analysis of the eCRF form will be 
considered for CEC adjudication. Non-IR triggers will 
be assessed after all the relevant source documentation 
has been requested to and provided by the participating 
sites and will be identified using a comprehensive search 
strategy that consider keywords logically related to the 
event. In general, key words with a clear relationship to 
the endpoint of interest (eg, for MI: unstable angina or 
ischaemic heart disease) will trigger a formal CEC review, 
whereas keywords with a potential relationship (eg, for 
MI: asystole, cardiac tamponade and hypertensive crisis) 
will trigger a review by a physician (independent from 
the CEC members) (online supplementary appendix). In 
the latter case, the event will undergo formal CEC review 
only if the reviewing physician will suspect an event. To 
limit possible reporting bias towards the null hypothesis 
(ie, querying for source documentation may stimulate 
a site to report previously unreported endpoints), only 
patients who have successfully completed the follow-up, 
data entry and all query processes for the parent study 
will be deemed eligible for the GLASSY study. For sites 
whose first language is not English, a mother tongue 
medical doctor will be involved for source documenta-
tion translation.
The first approval for GLASSY occurred on 18 April 
2017, and the first adjudication has been performed on 
6 September 2017.
stAtIstICAl AnAlysEs AnD sAMPlE sIzE ConsIDErAtIons
The coprimary efficacy endpoint will be first tested as 
non-inferiority followed by a superiority testing only if 
non-inferiority criteria will be met. As the experimental 
treatment is simpler than the control treatment, it may be 
useful in patients with low drug adherence and/or who 
become intolerant to aspirin. For this reason, GLASSY 
adopted a non-inferiority design for one of the two copri-
mary endpoints. The coprimary safety endpoint will be 
tested with a superiority hypothesis only. Alpha error will 
be evenly split (2.5% each) between the two coprimary 
endpoints. Based on best available data at the time of 
study design, the expected rate of the coprimary efficacy 
composite endpoint of death, non-fatal MI, non-fatal 
stroke or urgent TVR is 11% at 24 months in the control 
group. The expected rate of coprimary safety endpoint 
of type 3 or 5 BARC bleeding is 5% at 24 months in the 
control group. For the coprimary efficacy endpoint, 
non-inferiority will be declared if the upper limit of the 
95% CI for the experimental (ie, ticagrelor monotherapy) 
versus conventional arm at 24 months is less than 1.22 
on a risk ratio scale, corresponding to 2.2% absolute 
risk difference. A total of 3340 patients per group (6680 
patients) will yield 85% power to detect non-inferiority 
with a one-sided type I error (alpha) of 2.5%. The risk 
ratio will be calculated using the Mantel-Cox logrank 
method.
If non-inferiority will be met, 3593 patients per group 
(7186 patients) will provide 80% power to assess the supe-
riority for the coprimary efficacy endpoint at 24 months, 
assuming 20% relative risk reduction in the experimental 
arm and a two-sided alpha of 2.5%. A total of 7186 
patients will provide more than 80% power to detect a 
relative risk reduction of 33% in the experimental arm 
at 2 years with respect to coprimary safety endpoint of 
BARC 3 or 5 bleeding, setting the two-sided alpha error 
at 2.5%. For each trigger, the CEC-adjudicated events will 
be used if the evidence is sufficient and the IR endpoint 
if the evidence is not sufficient (ie, ‘best available’ data).
representativeness of the selected study cohort
There is no a priori attempt to select a patient popula-
tion in GLASSY that could be entirely representative of 
the whole population included in the parent study. This 
would require random selection of the sample at the 
patient level or at least at the site level which, although 
ideally desirable, would be financially unsustainable for 
an investigator-initiated study.
Importantly, in GLOBAL LEADERS, the randomisa-
tion was stratified by site. This means that GLASSY is a 
randomised substudy of the parent study, and therefore, 
the estimation of treatment effects are expected to be 
valid.
Baseline characteristics, quality indicators and risk 
profile of GLOBAL LEADERS patients according to 
GLASSY inclusion are presented in tables 1 and 2, with no 
significant interactions on any of the variables considered.
The estimated minimum sample size was 7186. There-
fore, to minimise the number of participating sites, only 
those with the highest recruitment rate based on the final 
number of included subjects were included. Accordingly, 
the top 19 recruiting sites would have provided an overall 
of 7365 patients. These 19 top-ranking recruitment sites 
were invited in Q1 2017 and all agreed to participate.
Local and, where deemed necessary, central insti-
tutional review approval was sought for all 19 partici-
pating sites in the form of either a protocol addendum 
or site-specific amendment. In Q1 2018, due to delays in 
getting study approved for the Bulgarian site ranked at 
19th position, the invitation to participate was extended 
to an additional site that was ranked at 20th position. This 
would allow reaching a final population of 7585 patients.
Evaluation of the concordance between Ir-adjudicated and 
CEC-adjudicated endpoints
Concordance between IR-adjudicated and CEC-adju-
dicated endpoints will be assessed in events with suffi-
cient evidence only. We will use the Cohen’s kappa with 
exact binomial 95% CIs as a measurement of the extent 
of agreement beyond chance alone. Cohen originally 
suggested the Kappa result be interpreted as follows: 
values ≤0 as indicating no agreement and 0.01–0.20 as 
none to slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 
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0.61–0.80 as substantial and 0.81–1.00 as almost perfect 
agreement. However, Cohen’s suggested interpretation 
was critiqued as too lenient for health-related studies, 
because it implies that a score as low as 0.41 might be 
acceptable. Therefore, we will interpret concordance 
between IR and CEC endpoints as follows:11
0–0.20: none.
0.21–0.39: minimal.
0.40–0.59: weak.
0.60–0.79: moderate
0.80–0.90: strong.
Above 0.90: almost perfect.
EthICs AnD DIssEMInAtIon
A complete list is attached in the online supplementary 
appendix. The study has been registered on ClinicalTrials.
Gov, a website that will be also used for reporting of study 
results and dissemination.
PAtIEnt AnD PublIC InvolvEMEnt
In GLASSY, the research question was developed to 
complement the investigator assessment. While patients 
were not directly involved in the design or conception 
of the study and no specific patient reported outcome 
has been considered, the extensive characterisation of 
several non-fatal endpoints is expected to provide a thor-
ough assessment of intervention on patient experience. 
GLASSY results will be disseminated to patients mainly via 
the local investigators. We especially take here the oppor-
tunity to thank all patients and families who volunteered 
to help others.
stuDy orgAnIsAtIon
The European Cardiovascular Research Institute (ECRI-
Trials B.V., Rotterdam, The Netherlands) will act as 
sponsor of this substudy. The leadership of the GLASSY 
is composed of the chair (Professor Stephan Windecker) 
and principal investigator (Professor Marco Valgimigli), 
in conjunction with the CEC members. Along with the 
executive committee of the parent study and one repre-
sentative for each included GLASSY site they will form the 
publication committee.
DIsCussIon
CECs are intended to enhance the scientific validity of a 
clinical trial through systematic, independent and stan-
dardised identification, processing and adjudication of 
suspected events. There are multiple lines of evidence 
indicating that central and independent adjudication of 
events may affect the results of a randomised trial by iden-
tifying clinically relevant unreported events,12–14 by mini-
mising variability and heterogeneity inherently present 
when several different clinicians and data managers apply 
definitions of endpoints that are complex and sometimes 
not well known,15 with implications on the interpreta-
tion of the effect of a randomised intervention.16 Finally, 
there has been an increasing regulatory emphasis on the 
requirement of an independent CEC.17–19
An analysis of the randomised  PURSUIT (Platelet 
Glycoprotein IIb/IIIa in  Unstable Angina: Receptor 
Suppression Using Integrilin Therapy) trial documented 
that site investigator and CEC assessments of whether a MI 
had occurred disagreed in 983 (20%) of the 5005 patients 
with suspected MI, mostly reflecting site misclassification 
Table 1 Baseline characteristics of GLOBAL LEADERS patients according to GLASSY inclusion
GLASSY
(20 sites)
No GLASSY
(110 sites)
P valuen=7585 n=8383
Age (years) n=7585, 64.9±10.3 n=8383, 64.2±10.3 0.41
Female n=7585, 1799 (23.7%) n=8383, 1915 (22.8%) 0.33
Hypertension n=7565, 5492 (72.6%) n=8349, 6223 (74.5%) 0.70
Diabetes mellitus n=7584, 1822 (24.0%) n=8373, 2216 (26.5%) 0.47
Renal failure (<60 eGFR) n=7567, 1005 (13.3%) n=8316, 1166 (14.0%) 0.83
Peripheral vascular disease n=7550, 553 (7.3%) n=8272, 452 (5.5%) 0.030
Current smoker n=7585, 2186 (28.8%) n=8383, 1983 (23.7%) 0.007
Previous myocardial infarction n=7575, 1762 (23.3%) n=8347, 1948 (23.3%) 0.91
Previous percutaneous coronary intervention n=7581, 2522 (33.3%) n=8373, 2699 (32.2%) 0.53
Previous coronary artery bypass grafting n=7581, 443 (5.8%) n=8374, 500 (6.0%) 0.62
Stable CAD n=7585, 3745 (49.4%) n=8383, 4736 (56.5%) 0.048
Multivessel treatment n=7585, 1098 (14.5%) n=8383, 1248 (14.9%) 0.65
Previous major bleeding or predisposition to bleeding n=7572, 48 (0.6%) n=8375, 50 (0.6%) 0.78
Mixed-models p values, accounting for a random effect of hospital identifier.
CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; GLASSY, GLOBAL LEADERS Adjudication Sub-StudY.
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of postenrolment MIs (as enrolment MIs) or under-re-
ported periprocedural MIs with a higher mortality asso-
ciated with CEC-identified MIs as compared with patients 
with no MI.12 Similarly, in post hoc analysis of two large 
randomised studies testing antithrombotic therapies in 
patients with coronary artery disease, CEC procedures 
identified more events (both ischaemia and bleeding) as 
compared with site investigators.13 14 Moreover, indepen-
dent adjudication of ischaemic and bleeding endpoints 
may provide important mechanistic information that may 
deepen understanding of the primary endpoint result of 
the study by better characterising components of such 
endpoints including, but not limited to cause of death, 
subtype of MI according to standardised definitions20 and 
bleeding location.
Also standardised adjudication processes provide the 
basis for consistency and reproducibility. In large vali-
dation effort of all-comer stent trials, a harmonisation 
process provided a high level of concordance for event 
adjudication and improved accuracy for final event 
reporting.15
Finally, the presence of a CEC has been strongly advo-
cated by regulatory authorities17 and requested in some 
instances for concern of bias in open-label studies.18 
Notably, regulatory authorities have been recently 
involved directly in endpoint definition along with inves-
tigators, pharmaceutical and CV device manufacturers 
and other stakeholders.19
GLASSY is a first of its kind scientific study designed to 
implement CEC processes in the context of a large phase III 
pragmatic trial intended to collect only IR endpoints. As such, 
it may provide unique information on how the adoption of 
CEC processes may affect study results. Some design features 
of an RCT, including blinding of randomised treatment 
and independent endpoint adjudication, may be complex, 
costly and challenging to implement in a pragmatic trial 
thus limiting study feasibility. However, these characteristics 
are important to enhance the scientific validity and quality 
of the evidence generated by minimising detection and/or 
reporting bias. GLASSY may indirectly allow to assess whether 
such bias(es) are present in GLOBAL LEADERS by quanti-
fying the concordance (or lack thereof) between IR-adjudi-
cated and CEC-adjudicated endpoints. In other words, to test 
the value of CECs. This could have relevant implications for 
the interpretation of the GLOBAL LEADERS results and to 
inform the design of similar studies in the future.
Table 2 Quality indicators and risk profile of GLOBAL LEADERS patients according to GLASSY inclusion
No of patients
GLASSY No GLASSY
P value
Interaction 
P valuen=7585 n=8383
All-cause mortality or new Q-wave MI or 
equivalentLBBBat 2 years
n=7585, 328 (4.3%) n=8383, 325 (3.9%) 0.16 0.77
All-cause mortality at 2 years n=7585, 247 (3.3%) n=8383, 230 (2.7%) 0.06 0.34
New Q-wave MI or equivalent LBBB at 2 years n=7585, 89 (1.2%) n=8383, 97 (1.2%) 0.93 0.34
BARC 3 or 5 bleeding at 2 years n=7585, 168 (2.2%) n=8383, 164 (2.0%) 0.26 0.90
BARC 1 bleeding at 2 years n=7585, 657 (8.7%) n=8383, 662 (7.9%) 0.08 0.59
Primary endpoint complete, n (%) n=7585 n=8383, <0.001 0.75
  Complete 7152 (94.3) 7683 (91.6)
  Vital status unknown 0 (0.0) 8 (0.1)
  Patient died post 2 years and ECG information 
unavailable
11 (0.1) 16 (0.2)
  Patient alive and ECG information unavailable 422 (5.6) 676 (8.1)
No of sites n=20 sites n=110 sites
No of protocol deviations/10 patients n=20, 0.4 (0.1 to 0.8) n=110, 0.6 (0.2 to 1.3) 0.14
Statin at discharge n=7547, 6954 (92.1%) n=8324, 7747 (93.1%) 0.78
Heart failure or left ventricular ejection fraction 
≤40% treated and ACE or ARB at discharge
n=251, 207 (82.5%) n=284, 232 (81.7%) 0.51
Heart failure or left ventricular ejection fraction 
≤40% treated and beta-blockers at discharge
n=157, 130 (82.8%) n=221, 181 (81.9%) 0.88
GLASSY includes 20 sites; no GLASSY includes 110 sites; total number of sites was 130.
P values from Mantel-Cox logrank test, interaction p value testing whether the GLASSY versus non-GLASSY sites modify the comparison 
experimental treatment strategy versus reference treatment strategy for the clinical outcomes. Protocol deviations compared with Mann-
Whitney U-test.
Protocol deviations included: inclusion/exclusion criteria, informed consent procedure, randomisation procedure, study procedures and safety 
reporting.
ARB, angiotensin receptor blockers; BARC, Bleeding Academic Research Consortium; GLASSY, GLOBAL LEADERS Adjudication Sub-StudY; 
MI, myocardial infarction; LBBB, left bundle branch block.
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Pragmatic clinical trials are fundamental to complement 
earlier phase studies designed to explore the efficacy of 
a given intervention. In addition, recent registry-based 
randomised trials have been appraised owing to their 
ability to address clinically relevant questions in large 
representative patient populations at limited cost. Pragma-
tism, an established concept in clinical research, aims at 
enhancing generalisability rather than internal validity of a 
study result and promote clinical or policy decision making 
by providing evidence for the adoption of a given interven-
tion into real-world clinical practice.21–23 To quantify the 
pragmatism of a clinical trial, tools have been proposed 
to examine whether key dimensions of a study—such as 
eligibility, recruitment and primary outcome—are directly 
related and relevant to usual care.24 Importantly, the role 
of independent endpoint adjudication in this context is 
a quality rather than a pragmatic issue. If the quality and 
consistency of endpoint ascertainment can be improved by 
adjudication without affecting routine patient care, CECs 
are highly desirable.25
A typical strength of CEC processes is to provide stan-
dardisation around secondary outcomes or subtype of 
events, such as characterisation of the modality of death, 
the location of a bleeding or the type of MI according 
to the universal Classification, that may be not reliably 
collected in the absence of standardised definitions and 
conventions. These data however, are important to fully 
characterise the efficacy and safety of an antithrom-
botic treatment intervention, such as that studied in 
the GLOBAL LEDERS study. According to best adjudi-
cation practice, GLASSY will collect and analyse exten-
sive outcome data, beyond the occurrence of the event 
itself, that were not considered in GLOBAL LEADERS 
CRF. Additionally, for each non-fatal suspected endpoint, 
we will assess if the documentation provided by the site 
was sufficient to understand whether the endpoint has 
occurred that may allow indirectly estimating the quality 
of endpoint reporting by the site.
limitations
An intrinsic limitation of GLASSY is that GLOBAL 
LEADERS has been designed as an IR-only study. There-
fore, systematic identification of study endpoints is 
limited by the eCRF and relies on source documentation 
provided by the site, which reduces the ability to identify 
all possible potential endpoints.
In addition, GLASSY, for logistical reasons, will be 
conducted in a representative sample rather than the 
entire parent study. Although a random sample would 
have been ideal in this setting, this was neither feasible 
or financially sustainable. The practical reason to focus 
enrolment for GLASSY to top enrolling centre may bias 
the study towards the null hypothesis of no difference 
between IR-adjudicated and CEC-adjudicated endpoint 
by selecting best enrolling sites. While this bias is possible, 
the relatively large study sample (≈50% of the parent 
study) makes this possibility unlikely.
ConClusIons
GLASSY will assess the scientific implications of CEC 
adjudication processes within a large RCT designed to 
collect only IR-reported events, to extend the assessment 
of the effectiveness and safety of the randomised inter-
vention tested in GLOBAL LEADERS to a broad range 
of non-fatal ischaemic and bleeding endpoints and ulti-
mately to test the value of standardised CEC processess 
within a pragmatic study design.
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